UK Clinical Vaccine Network Virtual Conference 2020

Bringing together and showcasing the work of the UK clinical vaccine community, to facilitate co-operation and collaborate on future challenges.

Register now

Due to ongoing uncertainties surrounding the current pandemic regulations, the faculty of CVNUK decided to replace this year’s physical conference with an online conference which took place on 27th November 2020. This features a variety of presentations focused on the development of a vaccine for Covid-19.

The recordings of the virtual conference are now available.
If you were unable to attend but would still like to view the sessions, please register via the button below and you will receive an email with a link to view the recorded sessions.

If you have any queries please email events@pagemedical.co.uk.

See below for the updated timetable.

@CVN_UK

Dr Helen McShane

Helen McShane is currently Director of the Oxford NIHR Biomedical Research Centre; Professor of Vaccinology at Oxford University; Deputy Head (Translation and Personnel), Medical Sciences Division; and an Honorary Consultant Physician in infectious diseases.

Helen obtained an intercalated BSc in 1988, followed by a degree in medicine in 1991 (both University of London). In 1997 She was awarded an MRC Clinical Training Fellowship to undertake a PhD with Adrian Hill in Oxford, and was later awarded a PhD in 2001 (University of London). In 2001 she was awarded a Wellcome Clinician Scientist Fellowship, allowing her to complete her clinical training and subsequently awarded a CCST in HIV and GU Medicine in 2003. In 2005 and 2010, she was awarded a Wellcome Senior Clinical Research Fellowship. She currently holds a Wellcome Trust Investigator Award. Helen was elected to be a fellow of the Academy of Medical Sciences in 2019.

Since 2001, Helen has lead a TB vaccine research group at the University of Oxford. She led the development of MVA85A, the first new TB vaccine candidate to enter efficacy testing. Current areas of focus include the development of controlled human mycobacterial challenge models, aerosol delivery of vaccines and immunomonitoring in clinical trials. She collaborates with several research groups across Africa in TB vaccine clinical trials.

Top